Laurent Chene

Laurent Chene is a prominent inventor based in Neuville aux Bois, France. He has made significant contributions to the field of cancer therapy through his innovative research and development of immunogenic compounds. With a total of nine patents to his name, Chene is recognized for his dedication to advancing medical science.

Latest Patents

Chene's latest patents include groundbreaking work on immunogenic compounds for cancer therapy. This invention relates to an immunogenic compound comprising an antigenic peptide that has amino acid similarity with a tumor antigen. The antigenic peptide is selected from a group of peptides that have similarity with IL13RA2, as described in the specification. Another notable patent focuses on microbiota sequence variants of tumor-related antigenic epitopes. This invention provides a method for identifying microbiota sequence variants of tumor-related antigenic epitope sequences, which are crucial for developing anticancer medicaments. These variants differ from self-antigens and can elicit a strong immune response, making them valuable in cancer immunotherapy.

Career Highlights

Chene is currently associated with Enterome S.A., a company dedicated to developing innovative therapies based on microbiome science. His work at Enterome has positioned him as a leader in the field of cancer immunotherapy, where he continues to explore new avenues for treatment.

Collaborations

Chene collaborates with notable colleagues, including Francesco Strozzi and Alban Mathieu. Their combined expertise enhances the research and development efforts at Enterome, fostering an environment of innovation and discovery.

Conclusion

Laurent Chene's contributions to cancer therapy through his patents and research are invaluable. His work not only advances scientific knowledge but also holds the potential to improve patient outcomes in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.